A solar eclipse occurs Monday -- what that means for solar producers may surprise you.

With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.

For several years, Procter & Gamble has been spinning off low-priority brands and cutting costs to streamline its business. But with little to show for those efforts, billionaire Nelson Peltz wants a seat at the table. Meanwhile, a slow summer blockbuster season is taking a major toll on theater operators.

Business development companies are undergoing a sea change as the asset class becomes more institutionalized.

Snap's quarterly update was... uninspiring. On this show, we talk about the updated user counts, ask some questions on engagement metrics, and run through the new financials.

Fracking has been the oil industry buzzword for years, here’s what the process actually means.

Scotts Miracle Gro could be the best marijuana stock to buy, while Illumina could be the best bet to capitalize on DNA-based medicine.

You might not be able to fire the coach or have a say in drafting new players, but there are ways to invest in professional sports.

Here's the differences between the major credit card processors, and how to evaluate them as investments.

We try and decode what's going on with Twitter's DAU/MAU numbers, and run through the figures on another banner quarter for the world's largest company.